- 1 Evaluation of sample collection and transport strategies to enhance yield, accessibility, and
- 2 biosafety of COVID-19 RT-PCR testing
- 4 Padmapriya Banada^a, David Elson^{a*}, Naranjargal Daivaa^{a*}, Claire Park^a, Samuel Desind^a, Ibsen
- 5 Montalvan^b, Robert Kwiatkowski^c, Soumitesh Chakravorty^{a,c}, David Alland ^{a,b#}, Yingda L. Xie ^{a,b#}
- ^aPublic Health Research Institute; Center for Emerging Pathogens, Rutgers New Jersey Medical
- 7 School, 185 S. Orange Av, Newark, NJ 07103; ^b University Hospital, 150 Bergen St, Newark, NJ
- 8 07103, ^cCepheid, Sunnyvale, CA.
- 9 Running Head: Enhanced sampling for COVID-19 RT-PCR
- 10 Key words: Saliva, Nasal, Oral, eNAT, Inactivation
- * Contributed equally

14

17

18

19

- 12 #Equal contribution corresponding authors: Address correspondence to Yingda Xie
- 13 ylx1@njms.rutgers.edu and David Alland allandda@njms.rutgers.edu
- 15 Conflicts of Interest: DA receives research support and royalty payments from Cepheid. RK and
- 16 SC are employed by Cepheid.

ABSTRACT

21

22

23

24

25

26

27

28

29

30

31

32

33

34

35

36

37

38

39

Sensitive, accessible, and biosafe sampling methods for COVID-19 reverse-transcriptase polymerase chain reaction (RT-PCR) assays are needed for frequent and widespread testing. We systematically evaluated diagnostic yield across different sample collection and transport workflows, including the incorporation of a viral inactivation buffer. We prospectively collected nasal swabs, oral swabs, and saliva, from 52 COVID-19 RT-PCR-confirmed patients, and nasopharyngeal (NP) swabs from 37 patients. Nasal and oral swabs were placed in both viral transport media (VTM) and eNATTM, a sterilizing transport buffer, prior to testing with the Xpert Xpress SARS-CoV-2 (Xpert) test. The sensitivity of each sampling strategy was compared using a composite positive standard. Overall, swab specimens collected in eNAT showed superior sensitivity compared to swabs in VTM (70% vs 57%, P=0.0022). Direct saliva 90.5%, (95% CI: 82%, 95%), followed by NP swabs in VTM and saliva in eNAT, was significantly more sensitive than nasal swabs in VTM (50%, P<0.001) or eNAT (67.8%, P=0.0012) and oral swabs in VTM (50%, P<0.0001) or eNAT (56%, P<0.0001). Saliva and use of eNAT buffer each increased detection of SARS-CoV-2 with the Xpert test; however, no single sample matrix identified all positive cases.

INTRODUCTION

40

41

42

43

44

45

46

47

48

49

50

51

52

53

54

55

56

57

58

59

60

61

62

Accurate, efficient, and biosafe detection of SARS-CoV-2 in both symptomatic and asymptomatic individuals with active COVID-19 infection is an essential public health strategy for preventing transmission and controlling the COVID-19 pandemic. Although nasopharyngeal (NP) swabs are a preferred specimen type, the invasiveness of this procedure, potential for variable collection quality, need for supervised collection with biohazard risks have hindered the scalability of this testing method ¹⁻⁴. Rather, there has been progress in establishing utility of non-invasive sampling methods that use saliva ⁵⁻⁷ or self-collected nasal or oral swabs ^{8,9} which can enable broader testing of at-risk populations and decrease exposure risk to healthcare workers ¹⁰. When combined with self-testing, wider implementation of rapid, CLIA-waived COVID-19 assays^{11,12} could dramatically increase public access to tests for SARS-COV-2 infection by expanding testing in atrisk locations including school and the workplace. However, the feasibility of scaling these noninvasive samples for widespread testing outside of carefully controlled environments remains limited by the operational and biosafety challenges. Our group has recently demonstrated that a guanidine-thiocyanate transport buffer (eNATTM, Copan diagnostics Murrieta, CA) leads to viral inactivation, with at least 5-log reduction in viable SARS-COV-2, and stabilization of viral RNA in a sample¹³. With the premise that eNAT could optimize testing yield while simplifying sample transport and handling, we evaluated and compared the yield of eNAT versus standard transport media, across different non-invasive samples, using the Cepheid Xpert Xpress SARS-COV-2 test ('Xpert'). Xpert is a FDA- EUA approved rapid, integrated, cartridge-based RT-PCR test that can be run on widely existing GeneXpert instruments used in over 130 countries. To our knowledge, this is the first study to demonstrate the use of a viral inactivating buffer across various non-invasive samples in a pointof-care test to deliver a complete and scalable work flow for biosafe handling and testing of

COVID samples.

63

64

65

66

67

68

69

70

71

72

73

74

75

76

77

78

79

80

81

82

83

84

85

MATERIALS AND METHODS

Study population and sample collection. To collect SARS-CoV-2 positive samples from COVID-19 PCR confirmed participants, we conducted a sub-study to an observational cohort study of COVID-19 patients at University Hospital (UH) affiliated with the Rutgers New Jersey Medical School in Newark, NJ, USA. This study was approved by the Rutgers Institutional Review Board for human subject research (Rutgers IRB # Pro2020001138). Eligible patients included adults (age ≥ 18) who tested SARS-CoV-2 PCR-positive by the in-hospital NP swab PCR tests (most commonly Simplexa COVID-19 Direct EUA (Diasorin Molecular LLC, Cypress, CA)). Patients that could not or did not consent, were pregnant or breastfeeding, prisoners, or who were unable to provide any respiratory specimens were excluded. Trained study personnel collected 1 NP swab (baseline only), 2 oral swabs, 2 nasal swabs, and a saliva sample from all participants who consented to all sample types. A subset of participants being evaluated for hospital outcomes in the parent study continued to be sampled longitudinally by oral swabs, nasal swabs, and saliva every 2-3 days until discharge. All swab types were immediately placed into 3mL of sterile Universal Viral Transport Medium (VTM; Labscoop, Little Rock, AR) whereas a second nasal and oral swab was collected and immediately placed into 3mL of eNAT (COPAN Diagnostics, Murrieta, CA, USA). A thinner nylon tip swab designed for nasopharyngeal (NP) sampling was used to obtain the NP swab (baseline only), and a thicker nylon tip swab designed for oral and nasal samples (Copan diagnostic, Murrieta, CA) was used for these sample types. NP swab collection was performed in accordance with CDC guidelines 14; oral swab collection was

87

88

89

90

91

92

93

94

95

96

97

98

99

100

101

102

103

104

105

106

107

108

performed by swabbing both buccal surfaces and tongue with an alternating order of collection for each media; nasal (anterior nares) swab collection was performed by rotating the swab 1 cm inside the nostril for 10-15 seconds, alternating nostrils for each media. Additionally, participants were instructed to self-collect a posterior saliva sample by clearing the back of their throat, then collecting 4 mL of saliva into a marked, empty, sterile wide-mouth cup (though any volume over 0.5 mL was accepted). All specimens were transported at room temperature and stored in a 2-4°C prior to testing, which occurred within 48 hours of sample collection. Testing by Xpert Xpress SARS-Cov-2 ('Xpert'). NP, nasal, and oral swabs were tested by adding 300ul of the sample (either in VTM or eNAT) directly to the Xpert SARS-Cov-2 test cartridges and the test was run in the GeneXpert system as per the manufacturer's instructions. The saliva sample was tested using three different methods. First, 300µl of the saliva sample was directly added into the Xpert test cartridge ("saliva direct" sample). Additionally, the same saliva sample was swabbed with two separate swabs (thicker nylon tip swabs) for 10 twirls followed by incubating each swab in the saliva for ~10-20 seconds ("saliva swab" sample). Each saliva swab sample was then transferred into test tubes containing 3mls of either VTM or 2 ml of eNAT buffer and mixed well. From each of these mixtures, 300µl were added directly to the sample chamber of Xpert cartridges. Saliva samples <300 ul were tested only by swabbing in eNAT and VTM. We also compared saliva samples directly diluted in 1:1, 1:2 and 1:4 ratios of saliva to eNAT. A minimum volume of 700µl of saliva was needed to test all saliva processing methods: 'saliva direct', saliva swab in eNAT and all three dilutions. For saliva samples with volumes less than 700µl, we prioritized saliva direct and saliva swab testing. Out of the 44-saliva direct positive samples tested with eNAT ratios, 1:1 dilution was not performed for one saliva sample due to insufficient volume. One each of the sample types had an error either due to pressure aborts (Error

2008) or probe check error (Error 5017) or instrument hardware error (Error 2025) and were not repeat tested. The saliva:eNAT mixtures were then tested using the GeneXpert system by adding 300µl of the mixture to the Xpert SARS-CoV-2 test cartridge. The effect on the assay inhibition, N2 gene cycle threshold (Ct), percent positive rate and cartridge pressure values were evaluated. **Definitions.** We compared samples that were collected contemporaneously (sample comparison set) and applied a composite SARS-CoV-2 positive reference standard, defined as at least one sample type being positive in the sample comparison set. We did not compare sample sets in which no samples were positive, as we reasoned that the PCR-negative samples from these individuals could not be considered false negative due to biologic variability in sampling over time, but they were also not suitable as true negative comparators due to known COVID status of these individuals. To confirm the discordancy that negative comparison sets was not due to difference in the in-hospital versus Xpert PCR tests, we obtained leftover media from positive NP swabs of a random subset of six participants. We then tested this archived sample as validation samples on Xpert. Xpert correctly detected SARS-CoV-2 in all six of these archived samples. Statistical analyses. Standard statistical analyses (average, standard deviation, and t-test) and proportion of positive tests by each sampling method were compared by Chi-square, t-test or ztest as appropriate, using Microsoft Excel 365 for Windows, GraphPad Prism version 8 or online software (http://vassarstats.net/propdiff_ind.html). Scatter plots for Ct values showing the mean and SD were included for the positive samples.

RESULTS

109

110

111

112

113

114

115

116

117

118

119

120

121

122

123

124

125

126

127

128

131

132

133

134

135

136

137

138

139

140

141

142

143

144

145

146

147

148

149

150

151

152

Participant enrollment and characteristics. Between June 12th, 2020 and October 23rd, 2020, 70 subjects were enrolled into the study (Figure 1). From these 70 enrollees, a total of 116 sample comparison sets were collected - 70 at baseline and 46 at follow-up time-points. Of note, some participants consented to all sample types except for NP swabs. Of the 116 comparison sets, 84 sample sets from 52 participants were complete with all specimen types and had at least one sample positive (by the composite reference standard) and were thus included in the sample comparison analysis (Fig. 1). Characteristics of the 52 participants in the analysis population (participants with at least one study sample positive for SARS-CoV-2) are shown in Table 1 and characteristics of the 13 participants with all negative samples are shown in Supplementary Table S1. Among the 52 participants in the analysis population, 41 (79%) had symptoms potentially consistent with COVID whereas 11 (21%) of these participants presented to the hospital for non-COVID indications, had no respiratory symptoms, and were incidentally found to be COVID-positive. Average participant age was 55, 37% were female, and the most common comorbidities were hypertension and diabetes. On average, the baseline collection took place 2 days after the last positive in-hospital NP swab PCR test for participants in the analysis group, and 3 days for participants with no positive samples. The biologic variability of PCR positivity from samples collected several days apart was evident in the discordancy of longitudinal in-hospital NP swab PCR testing results even when the same test was used. Nineteen (38%) of the 52 participants in the analysis group had at least one subsequent negative in-hospital NP swab PCR test during their hospital admission (Table 1). Additionally, we validated 100% agreement of the in-house test with Xpert (all the original samples were Xpert positive) from the original left-over positive NP swab specimen of 6 participants. These observations support that positive-negative discordancy across time was likely

154

155

156

157

158

159

160

161

162

163

164

165

166

167

168

169

170

171

172

173

174

175

biologic or sampling variability and unlikely due to discordancy between the in-hospital and Cepheid tests, and is consistent with previous comparative performance of Xpert Xpress SARS-CoV-2 with other SARS-CoV-2 RT-PCR platforms ^{11, 15, 16}. Comparative testing of different respiratory specimens in Xpert Xpress SARS-COV-2. A total of 84 sample comparison sets from 52 patients were included in the sample comparison analysis based on the composite reference, where at least one specimen in the comparison set was positive. Seventeen of these patients had follow-up samples collected on alternative days during their hospital stay. Thus, a total of 84 sets of all specimen types were included in the analysis except for NP swabs, which were only collected from 51 completed baseline collections. Of the 51 completed baseline collections, 14 participants declined NP swab, leaving a total of 37 sample sets that could be analyzed with NP swab. As shown in Fig. 2A, undiluted saliva added directly to the cartridge ('direct saliva') gave the highest detection rate at 90.5% (76/84), followed by NP-VTM (86.5%, 32/37) and saliva in eNAT buffer (84.5%; 71/84), which were significantly higher compared to nasal or oral swabs (P<0.0001). Saliva in VTM (71.4%; 60/84) also performed better than oral swabs in VTM (50%; 42/84) or eNAT (58%; 49/84), as well as nasal swabs in VTM (50%; 42/84) or eNAT (67.8%; 57/84). We further analyzed N2-gene cycle threshold (Ct) values for all positive samples as shown in Fig. 2B. Average N2 gene Ct values were the earliest for NP-VTM (32±5.4) and saliva direct (Ct=34.2±5.8) and most delayed for oral-VTM (37.5±4.9). The Ct range difference was statistically significant between saliva direct and oral-VTM (P<0.0001), oral-eNAT (P=0.0003) and saliva-VTM (P=0.0026). However, there was no significant difference of N2-Ct range for NP-VTM (P=0.28), nasal-VTM (P=0.09), nasal-eNAT (P=0.82) and saliva-eNAT (P=0.26) compared to saliva direct (Fig. 2B). There were three negative NP specimens that were detected in saliva,

177

178

179

180

181

182

183

184

185

186

187

188

189

190

191

192

193

194

195

196

197

198

which we observed to have N2 Ct values of 39.4, 40.3 and 36.1 (Supplementary Fig. 1C), indicating below LOD level viral loads ¹⁷ possibly contributing to the discrepancy. Only one of the sample sets was positive by NP swab (Ct=35.4) but negative in saliva direct and both saliva swabs (VTM and eNAT). Overall, we found that saliva performed better or equal to NP swabs in detecting COVID positive patients. Similarly, the samples that were negative by other respiratory specimens (nasal or oral swab) but detected by saliva swab in VTM or eNAT had an overall delayed N2-Ct values of >37, indicating better performance in saliva for samples with low viral load (sub-LoD) or lesser variation in saliva collection. Influence of transport media on detection across all sample types. We also evaluated if the composition of different transport media, specifically VTM and eNAT, had any influence on the detection sensitivity. As described, nasal and oral swabs were collected in both VTM and eNAT whereas saliva was collected from patients in an empty sterile cup, then subsequently swabbed and stored in VTM and eNAT. As shown before in Fig. 2A, compared to VTM, eNAT increased the positivity rate by about 20% (40/84 vs 57/84) for nasal swabs (P=0.008), followed by 12% for saliva (60/84 vs 70/84, P=0.065) and 6% for oral swabs (42/84 vs 47/84, P=0.43). When data from all sample types were combined to compare the two media, eNAT offered over 12% advantage (142 vs 174 out of 252 samples) in overall detection rate compared to VTM (P=0.003). Optimizing the use of eNAT buffer for saliva. Compared to saliva swabbed into eNAT, direct saliva yielded an overall delayed SPC-Ct values in the Xpert test, indicating possible PCR inhibition and increased (>60 PSI) in-cartridge pressure values (Supplementary Fig. 2B). Saliva diluted into eNAT at a ratio of 1:2 (N=43) yielded the second highest PCR positive rate (97.7%, 42/43) after saliva direct (100%, 43/43) (Fig. 3). Dilutions of 1:1 and 1:4 yielded 95% (40/42) and 93% (40/43) positive rate, respectively. Saliva swabs in eNAT showed the lowest sensitivity at

200

201

202

203

204

205

206

207

208

209

210

211

212

213

214

215

216

217

218

219

220

221

86% (37/43, P>0.05; Fig. 3A). A sample missed by 1:2 &1:4 dilutions and another by 1:1 & 1:4 dilutions, had delayed N2-Ct values of 44.3 and 41.7 with saliva direct, respectively, indicating the influence of Poisson distribution for viral loads considerably below the limit of detection. Whereas the average N2-Ct values were similar (ca. 33-34) for all saliva conditions tested (P>0.05), the SPC-Ct values were earlier with saliva in eNAT compared to saliva direct (31.25±1.74, P<0.001, Supplementary Fig. 2C), suggesting that PCR inhibition was mitigated by the addition of eNAT to an appreciable extent. Operational characteristics of processing saliva in GeneXpert cartridges: To evaluate saliva processing profiles in the GeneXpert cartridges, we analyzed the sample processing control (SPC) Ct values and in-cartridge pressure values. All respiratory samples collected in either VTM or eNAT did not have any significant difference either with SPC Ct or the max pressure values (Supplementary Fig. 2A and 2B). Saliva direct, the only sample type analyzed as is without dilution, yielded slightly delayed SPC Ct and higher cartridge pressure values with an average of 58±13.48, with one sample aborting the run due to pressure exceeding 100 psi (vs NP-VTM, P<0.0001). However, when the saliva was swabbed and transferred to VTM or eNAT, average pressure values fell to 53.2 ± 6.06 (P<0.0001) and 52.2 ± 5.4 (P<0.0001), respectively. Dilution with eNAT at 1:1, 1:2 and 1:4 ratio reduced the inhibition from saliva direct (P<0.0001) by lowering the average SPC-Ct values by ~2 ct values (Ct 29.1 in 1:2 vs 31.2 in saliva direct). There was no significant difference in maximum in-cartridge pressure values with saliva dilution in eNAT (P>0.05), except for swab in eNAT (P=0.02). These results suggest that particles or mucus present in direct saliva samples can occasionally interfere with assay function, and that swab testing may be considered when these situations occur.

DISCUSSION

222

223

224

225

226

227

228

229

230

231

232

233

234

235

236

237

238

239

240

241

242

243

244

We found that saliva is an excellent test matrix for the Xpert Xpress SARS-CoV-2 test, providing a sensitivity that is comparable to NP swabs and better than nasal and oral swabs. This finding is consistent with previously published studies using other RT-qPCR modalities ¹⁸⁻²³. Although a handful of previous studies have looked at saliva tested in the Xpert SARS-CoV-2 11, 24, 25, to our knowledge this study is the first study to comprehensively test multiple non-invasive sampling methods, in the setting of both symptomatic and asymptomatic SARS-COV-2 infection, with and without the use of a sterilizing sample/transport buffer. By applying a composite reference standard for a positive sample, we observed that saliva enhanced the detection of SARS-CoV-2 compared all other sampling types. This finding may be largely attributable to more reliable SARS-CoV-2 yield with saliva sampling as opposed to higher variability of swab sampling, consistent with similar observations from other studies ^{1,5-7}. It is worth noting that noB sample matrix was 100% sensitive compared to the composite reference standard. Discordancy between sample matrices was most pronounced in samples that had a delayed cycle threshold indicating low viral load. This suggests that testing with multiple samples and perhaps multiple sample types when clinical suspicion is high may provide the highest sensitivity and negative predictive value for SARS-CoV-2. We additionally found that eNAT, a buffer we have previously determined to be effective at inactivating SARS-CoV-2 in-vitro (Banik et al., submitted), increased the test positivity rates across all sample types compared to VTM (P=0.0032), with a saliva to eNAT ratio of 1:2 being optimal in our sample set. We also found that adding eNAT to saliva possibly mitigates the PCR interference from saliva with lower pressure values and recovery of otherwise delayed SPC Ct values seen with direct saliva. These findings suggest that the application of eNAT as a sample

246

247

248

249

250

251

252

253

254

255

256

257

258

259

260

261

262

263

264

265

266

buffer may be advantageous not only in safe handling and transport, but also in improving yield and processing capability on the Cepheid system. There were several limitations in this study. First, there were less contemporaneous NP swabs collected with saliva, thereby reducing the number of direct comparisons between these two sample types, although they were found to be comparable. An underlying reason for this – participants declining NP swab collection due to its discomfort – also demonstrates the real-world limitations that would be magnified with larger scale testing such as in schools or the workplace. Secondly, we added eNAT to saliva in the laboratory, whereas the benefit of eNAT would be to sterilize samples immediately after collection and before transport and test set up. However, this allowed us to evaluate the combination of eNAT and saliva under different conditions and inform optimal design of kits to add eNAT immediately to saliva upon collection. Finally, our participants were patients who had either been admitted to the hospital or seen in the emergency department. This population may not be generalizable to ambulatory individuals who would benefit the most from self-collection. However, we captured a diverse patient group in our cohort including those who were never admitted, as well as patients who were detected by universal screening but reported no COVID symptoms. Altogether, our findings support the use of saliva and eNAT sterilizing buffer to enhance effective, safe, and accessible COVID testing and screening in the many health care systems worldwide already using GeneXpert instruments.

Acknowledgements: We thank Dr. Jason H. Yang (Rutgers New Jersey Medical School) for supporting DE's and CP's role in the studies, Cepheid for in-kind donation of cartridges, and Copan for donation of eNAT media and swabs. This study was partially funded by the National Institute of Allergy and Infectious Diseases of the National Institutes of Health under award number R01 AI131617 and Rutgers University Institutional Support.

References

- 287 [1] Qian Y, Zeng T, Wang H, Xu M, Chen J, Hu N, Chen D, Liu Y: Safety management of nasopharyngeal
- specimen collection from suspected cases of coronavirus disease 2019. Int J Nurs Sci 2020, 7:153-6.
- 289 [2] Jayamohan H, Lambert CJ, Sant HJ, Jafek A, Patel D, Feng H, Beeman M, Mahmood T, Nze U, Gale BK:
- 290 SARS-CoV-2 pandemic: a review of molecular diagnostic tools including sample collection and
- 291 commercial response with associated advantages and limitations. Analytical and Bioanalytical Chemistry
- 292 2020.

- 293 [3] Kinloch NN, Ritchie G, Brumme CJ, Dong W, Dong W, Lawson T, Jones RB, Montaner JSG, Leung V,
- 294 Romney MG, Stefanovic A, Matic N, Lowe CF, Brumme ZL: Suboptimal Biological Sampling as a Probable
- 295 Cause of False-Negative COVID-19 Diagnostic Test Results. The Journal of Infectious Diseases 2020,
- 296 222:899-902.
- 297 [4] Surkova E, Nikolayevskyy V, Drobniewski F: False-positive COVID-19 results: hidden problems and
- 298 costs. The Lancet Respiratory Medicine.
- 299 [5] Pasomsub E, Watcharananan SP, Boonyawat K, Janchompoo P, Wongtabtim G, Suksuwan W,
- 300 Sungkanuparph S, Phuphuakrat A: Saliva sample as a non-invasive specimen for the diagnosis of
- 301 coronavirus disease 2019: a cross-sectional study. Clin Microbiol Infect 2020.
- 302 [6] Vaz SN, Santana DS, Netto EM, Pedroso C, Wang WK, Santos FDA, Brites C: Saliva is a reliable, non-
- invasive specimen for SARS-CoV-2 detection. Braz J Infect Dis 2020.
- 304 [7] Wyllie AL, Fournier J, Casanovas-Massana A, Campbell M, Tokuyama M, Vijayakumar P, Warren JL,
- 305 Geng B, Muenker MC, Moore AJ, Vogels CBF, Petrone ME, Ott IM, Lu P, Venkataraman A, Lu-Culligan A,
- Klein J, Earnest R, Simonov M, Datta R, Handoko R, Naushad N, Sewanan LR, Valdez J, White EB, Lapidus
- 307 S, Kalinich CC, Jiang X, Kim DJ, Kudo E, Linehan M, Mao T, Moriyama M, Oh JE, Park A, Silva J, Song E,
- 308 Takahashi T, Taura M, Weizman OE, Wong P, Yang Y, Bermejo S, Odio CD, Omer SB, Dela Cruz CS,
- 309 Farhadian S, Martinello RA, Iwasaki A, Grubaugh ND, Ko AI: Saliva or Nasopharyngeal Swab Specimens
- 310 for Detection of SARS-CoV-2. N Engl J Med 2020, 383:1283-6.
- 311 [8] McCulloch DJ, Kim AE, Wilcox NC, Logue JK, Greninger AL, Englund JA, Chu HY: Comparison of
- 312 Unsupervised Home Self-collected Midnasal Swabs With Clinician-Collected Nasopharyngeal Swabs for
- 313 Detection of SARS-CoV-2 Infection. JAMA Network Open 2020, 3:e2016382-e.
- 314 [9] Tu Y-P, Jennings R, Hart B, Cangelosi GA, Wood RC, Wehber K, Verma P, Vojta D, Berke EM: Swabs
- 315 Collected by Patients or Health Care Workers for SARS-CoV-2 Testing. New England Journal of Medicine
- 316 2020, 383:494-6.
- 317 [10] To KK, Tsang OT, Yip CC, Chan KH, Wu TC, Chan JM, Leung WS, Chik TS, Choi CY, Kandamby DH, Lung
- DC, Tam AR, Poon RW, Fung AY, Hung IF, Cheng VC, Chan JF, Yuen KY: Consistent Detection of 2019
- Novel Coronavirus in Saliva. Clin Infect Dis 2020, 71:841-3.
- 320 [11] Chen JH, Yip CC, Poon RW, Chan KH, Cheng VC, Hung IF, Chan JF, Yuen KY, To KK: Evaluating the use
- 321 of posterior oropharyngeal saliva in a point-of-care assay for the detection of SARS-CoV-2. Emerg
- 322 Microbes Infect 2020, 9:1356-9.
- 323 [12] Ravi N, Cortade DL, Ng E, Wang SX: Diagnostics for SARS-CoV-2 detection: A comprehensive review
- of the FDA-EUA COVID-19 testing landscape. Biosensors and Bioelectronics 2020, 165:112454.
- 325 [13] Banik S, Saibire K, Suryavanshi S, Johns G, Chakravorty S, Kwiatkawoski R, Alland D, Banada PP:
- 326 Inactivation of SARS-CoV-2 virus in saliva using a guanidium based transport medium suitable for RT-PCR
- 327 diagnostic assays. medRxiv 2021:2021.01.15.21249891.
- 328 [14] CDC: Interim Guidelines for Collecting, Handling, and Testing Clinical Specimens for COVID-19. 2020.
- 329 [15] Lieberman JA, Pepper G, Naccache SN, Huang ML, Jerome KR, Greninger AL: Comparison of
- 330 Commercially Available and Laboratory-Developed Assays for In Vitro Detection of SARS-CoV-2 in Clinical
- 331 Laboratories. J Clin Microbiol 2020, 58.

- 332 [16] Zhen W, Manji R, Smith E, Berry GJ: Comparison of Four Molecular In Vitro Diagnostic Assays for the
- 333 Detection of SARS-CoV-2 in Nasopharyngeal Specimens. J Clin Microbiol 2020, 58.
- 334 [17] Loeffelholz MJ, Alland D, Butler-Wu SM, Pandey U, Perno CF, Nava A, Carroll KC, Mostafa H, Davies
- E, McEwan A, Rakeman JL, Fowler RC, Pawlotsky JM, Fourati S, Banik S, Banada PP, Swaminathan S,
- Chakravorty S, Kwiatkowski RW, Chu VC, Kop J, Gaur R, Sin MLY, Nguyen D, Singh S, Zhang N, Persing DH:
- 337 Multicenter Evaluation of the Cepheid Xpert Xpress SARS-CoV-2 Test. J Clin Microbiol 2020, 58.
- 338 [18] Alizargar J, Etemadi Sh M, Aghamohammadi M, Hatefi S: Saliva samples as an alternative for novel
- coronavirus (COVID-19) diagnosis. J Formos Med Assoc 2020, 119:1234-5.
- 340 [19] Azzi L, Baj A, Alberio T, Lualdi M, Veronesi G, Carcano G, Ageno W, Gambarini C, Maffioli L, Saverio
- 341 SD, Gasperina DD, Genoni AP, Premi E, Donati S, Azzolini C, Grandi AM, Dentali F, Tangianu F, Sessa F,
- Maurino V, Tettamanti L, Siracusa C, Vigezzi A, Monti E, Iori V, Iovino D, Ietto G, Grossi PA, Tagliabue A,
- Fasano M: Rapid Salivary Test suitable for a mass screening program to detect SARS-CoV-2: A diagnostic
- accuracy study. J Infect 2020, 81:e75-e8.
- 345 [20] Chu AW, Chan WM, Ip JD, Yip CC, Chan JF, Yuen KY, To KK: Evaluation of simple nucleic acid
- extraction methods for the detection of SARS-CoV-2 in nasopharyngeal and saliva specimens during
- global shortage of extraction kits. J Clin Virol 2020, 129:104519.
- 348 [21] Lai CKC, Chen Z, Lui G, Ling L, Li T, Wong MCS, Ng RWY, Tso EYK, Ho T, Fung KSC, Ng ST, Wong BKC,
- Boon SS, Hui DSC, Chan PKS: Prospective Study Comparing Deep Throat Saliva With Other Respiratory
- 350 Tract Specimens in the Diagnosis of Novel Coronavirus Disease 2019. J Infect Dis 2020, 222:1612-9.
- 351 [22] Nagura-Ikeda M, Imai K, Tabata S, Miyoshi K, Murahara N, Mizuno T, Horiuchi M, Kato K, Imoto Y,
- 352 Iwata M, Mimura S, Ito T, Tamura K, Kato Y: Clinical Evaluation of Self-Collected Saliva by Quantitative
- 353 Reverse Transcription-PCR (RT-qPCR), Direct RT-qPCR, Reverse Transcription-Loop-Mediated Isothermal
- Amplification, and a Rapid Antigen Test To Diagnose COVID-19. J Clin Microbiol 2020, 58.
- 355 [23] Hanson KE, Barker AP, Hillyard DR, Gilmore N, Barrett JW, Orlandi RR, Shakir SM: Self-Collected
- 356 Anterior Nasal and Saliva Specimens versus Health Care Worker-Collected Nasopharyngeal Swabs for the
- 357 Molecular Detection of SARS-CoV-2. J Clin Microbiol 2020, 58.
- 358 [24] McCormick-Baw C, Morgan K, Gaffney D, Cazares Y, Jaworski K, Byrd A, Molberg K, Cavuoti D: Saliva
- as an Alternate Specimen Source for Detection of SARS-CoV-2 in Symptomatic Patients Using Cepheid
- 360 Xpert Xpress SARS-CoV-2. J Clin Microbiol 2020, 58.

364

365

366

367

368

- 361 [25] Wong RC, Wong AH, Ho YI, Leung EC, Lai RW: Evaluation on testing of deep throat saliva and lower
- respiratory tract specimens with Xpert Xpress SARS-CoV-2 assay. J Clin Virol 2020, 131:104593.

371

372

373

374

375

376

377

378

379

380

381

382

383

384

385

Figure Legends. Figure 1. Study flowchart. Figure 2. Comparative testing of different respiratory specimens using the Xpert Xpress SARS-COV-2 test. (A) Percent positive rate and (B) N2 gene cycle threshold (Ct) values of samples from all participants with at least one SARS-COV-2 positive sample (N=84 for all samples and N=37 for NP swab). NP=Nasopharyngeal: VTM=Viral transport medium; eNAT= eNATTM transport media, Copan diagnostics. ns=not statistically different. **** P<0.0001; ***P<0.001, **P=0.02 Figure 3. eNAT as a transport media for saliva. Saliva diluted with eNAT at 1:1, 1:2, and 1:4 ratio showing (A) Percent positive rate and (B) N2-Ct values from patient saliva samples tested directly (N=44), as a swab in eNAT (N=44), diluted 1:1 (N=44), 1:2 (N=42), and 1:4 (N=42) in eNAT transport media. ns=not statistically significant.

Table 1. Characteristics of participants in the analysis population (participants with at least one study sample positive for SARS-CoV-2).

	Analysis population (N=52)
Mean Age in years (SD)	55 (15.1)
# of Men (%)	33 (63%)
# of Women (%)	19 (37%)
Ethnicity (%)	
Hispanic	35 (67%)
Black	15 (29%)
White	2 (4%)
Comorbidities	
Hypertension	27 (52%)
Diabetes Mellitus	16 (31%)
Coronary Artery Disease	7 (13%)
Chronic Kidney Disease	4 (8%)
Lung Disease (eg, COPD)	8 (15%)
No chronic disease	19 (36%)
COVID symptoms (%)	. ,
Cough	33 (64%)
Shortness of breath	32 (62%)
Fever	31 (60%)
Diarrhea	13 (25%)
Chest Pain	10 (19%)
No COVID symptoms	11 (21%)
Oxygen Support Required (%)	
None	20 (38%)
Nasal Canula	29 (56%)
Non-Invasive Mechanical Ventilation	2 (4%)
Intubation	1 (2%)
Symptom duration prior to baseline collection Mean (range)	7 days (1 – 23 days)
Days between in-hospital NP swab PCR and baseline collection: mean (range)	2 days (0 – 10 days)
Number of follow-up time-points per participant: mean (range)	1.5 (0 – 10)
Participants with negative NP swab PCR collected in clinical follow-up during hospitalization	19 (38%)





